• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Adjunctive methylprednisolone treatment for hepatitis B acute-on-chronic liver failure associated with increased survival

byConstance Wu
December 23, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

LI-RADS outlines standards for liver imaging studies assessing HCC [Classics Series]

#VisualAbstract: Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial

The Child-Pugh score: Prognosis in chronic liver disease and cirrhosis [Classics Series]

1. Adding methylprednisolone to standard treatment in hepatitis B virus-related acute-on-chronic liver failure was associated with an increase in 6-month survival rate.

Evidence Rating Level: 1 (Excellent)

Hepatitis B virus-related acute-on-chronic liver failure (HVB-ACLF), accounting for 70% of all ACLF cases in Asia, is a severe exacerbation of liver function leading to high mortality rates. WIth liver transplantation as the only curative treatment, there is a lack of efficacious treatment options for these patients. As systemic inflammation secondary to a cytokine storm is a key feature of ACLF, methylprednisolone (MP) has been theorized to play a role in its treatment; particularly when combined with nucleoside analogs (NAs), this combination may reverse potential HBV-related liver deterioration. However, the use of MP in HBV-ACLF remains uncertain and controversial. In this multicentre, prospective randomized controlled clinical trial, 171 patients (mean age 45.2 years, 88.9% men) with HBV-ACLF were recruited from three medical centres in Beijing. They were randomized in a 1:1 ratio to receive either MP (1.5mg/kg/day IV for 3 days, 1mg/kg/day IV for 2 days, then 0.5mg/kg/day IV for 2 days) plus standard treatment or standard treatment only (the control group). At 6 months, the mortality rate of the MP group was lower than the control group (32.4% vs 42.5%, p=0.0037), while there was no significant difference in liver transplants between the groups. The univariate analysis and collinearity diagnosis showed that MP was an independent predictor for mortality among HBV-ACLF patients (HR 0.547, p=0.040). Cox analysis identified HBV DNA and lymphocyte/monocyte ratios (LMRs) as predictors of mortality, in the MP group. In terms of adverse events, incidence of hypoalbuminemia (56.6% vs 37.5%, p=0.012), fungal infection, ascites, hepatic encephalopathy, and new onset infection (41.1% vs 31.8%, p=0.214) were higher in the MP group. While the timing of MP administration plays a major role in treatment efficacy, most patients were transferred to the medical centres after spending a median of 16 days and 20 days in primary care, in the MP and control groups respectively. As this study could not determine the significance of MP onset time, future studies should explore this factor when evaluating the potential efficacy of MP therapy in HBV-ACLF.

Click to read the study in BMC Medicine

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chronic liver diseasehepatitis bHepatitis B virus-related acute-on-chronic liver failureliverliver failuremethylprednisolone
Previous Post

Video laryngoscopy improves the first-attempt success rate of orotracheal intubation in infants

Next Post

#Visual Abstract: Special Report: Vaccines in Development Part 1: Pfizer/BioNTech vaccine first to receive emergency use authorization

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

LI-RADS outlines standards for liver imaging studies assessing HCC [Classics Series]

August 12, 2022
#VisualAbstract: Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial
StudyGraphics

#VisualAbstract: Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial

June 2, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
General Medicine Classics

The Child-Pugh score: Prognosis in chronic liver disease and cirrhosis [Classics Series]

December 3, 2021
Spleen elastography may be effective in the diagnosis of portal hypertension
Chronic Disease

Maralixibat appears safe and efficacious for patients with Alagille syndrome and cholestatic pruritus

November 9, 2021
Next Post
#Visual Abstract: Special Report: Vaccines in Development Part 1: Pfizer/BioNTech vaccine first to receive emergency use authorization

#Visual Abstract: Special Report: Vaccines in Development Part 1: Pfizer/BioNTech vaccine first to receive emergency use authorization

AAP supports mandatory influenza vaccination of health care providers

Special Report: Vaccines in Development Part 3: Oxford/AstraZeneca vaccine showing promise

#VisualAbstract: Neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen shows high cost-effectiveness for ERBB2-positive breast cancer

#VisualAbstract: Neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen shows high cost-effectiveness for ERBB2-positive breast cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Provision of 1-year mortality data for patients hospitalized with heart failure does not influence clinical decision-making – The REVEAL-HF trial
  • Genetic risk for hemochromatosis associated with abnormal iron deposition localized to motor circuits of the brain
  • Graded sensorimotor retraining may improve chronic lower back pain compared to sham procedure: The RESOLVE randomized clinical trial
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.